Brief: Medipal Recieves Orphan Drug Designation For JR-446 For Mucopolysaccharidosis Type IIIB
29/09/2025 18:01
Sept 29 (Reuters) - MEDIPAL: MEDIPAL - NOTICE OF ORPHAN DRUG DESIGNATION FOR JR-446 FOR MUCOPOLYSACCHARIDOSIS TYPE IIIB BY MINISTRY OF HEALTH, LABOUR AND WELFARE OF JAPAN ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medipal Holdings
See all newsBrief: Medipal Holdings Corp Says It Will Buy Back Up To 2% Of Own Shares Worth 10 Billion Yen
Table: Medipal Holdings -2026/27 group forecast
Brief: Medipal Holdings Announces It Has Received Demand For EGM From Shareholder Silchester International Investors
Brief: Silchester International Raises Stake In Medipal Holdings Corp To 11.96% From 11.73%, Filing Shows
Brief: Silchester To Make Proposals Regarding Higher Dividend, Share Buyback, Share Retirement, Composition Of Board Of Directors If No Improvement In Dialogue With Medipal Holdings, Filing Shows